Volume 67, Issue 2, Pages (February 2005)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 62, Issue 4, Pages (October 2002)
Volume 60, Issue 6, Pages (December 2001)
Volume 55, Issue 3, Pages (March 1999)
Sodium thiosulfate prevents vascular calcifications in uremic rats
Volume 73, Issue 3, Pages (February 2008)
Volume 23, Issue 2, Pages (February 2016)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 62, Issue 4, Pages (October 2002)
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy  J.-A. Moon,
Volume 115, Issue 1, Pages (July 1998)
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes  Lesley Wassef, Darren J. Kelly, Richard E. Gilbert 
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats  Eduardo Slatopolsky, Mario Cozzolino,
Vitamin E attenuates crystal formation in rat kidneys: Roles of renal tubular cell death and crystallization inhibitors  H.-S. Huang, J. Chen, C.-F. Chen,
Figure S4 A C Vehicle control AC0010 (300mg/kg) Gefitinib (50mg/kg) D
Vitamin E treatment of experimental glomerular disease in rats
Volume 60, Issue 6, Pages (December 2001)
Volume 59, Issue 5, Pages (May 2001)
Volume 76, Pages S50-S99 (August 2009)
Volume 65, Issue 2, Pages (February 2004)
Graphic Interpretation of Serum Parathyroid Hormone, Calcium, and Phosphorus Values in Primary Hyperparathyroidism  Pai C. Kao, Ph.D., Edward G. Lufkin,
Volume 60, Issue 1, Pages (July 2001)
Volume 72, Issue 8, Pages (October 2007)
Calcium citrate ameliorates the progression of chronic renal injury
Use of vitamin D in chronic kidney disease patients
Tight blood pressure control decreases apoptosis during renal damage
Volume 87, Issue 2, Pages (February 2015)
Volume 67, Pages S33-S36 (June 2005)
Volume 54, Issue 3, Pages (September 1998)
Metabolic acidosis inhibits soft tissue calcification in uremic rats
Volume 69, Issue 3, Pages (February 2006)
Volume 74, Issue 10, Pages (November 2008)
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism 
Volume 57, Issue 2, Pages (October 2000)
Volume 55, Issue 1, Pages (January 1999)
Resistance to ischemic acute renal failure in the Brown Norway rat: A new model to study cytoprotection  David P. Basile, Deborah Donohoe, X.I.A. Cao,
Volume 56, Issue 3, Pages (September 1999)
Volume 68, Pages S24-S28 (July 2005)
M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
Volume 69, Issue 3, Pages (February 2006)
Volume 55, Issue 4, Pages (April 1999)
Volume 74, Issue 1, Pages (July 2008)
Volume 87, Issue 3, Pages (March 2015)
Volume 59, Issue 3, Pages (March 2001)
Volume 60, Issue 6, Pages (December 2001)
Eva Balint, Cory F. Marshall, Dr Stuart M. Sprague 
Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials  Christof Westenfelder, Florian E. Togel 
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
Volume 62, Issue 3, Pages (September 2002)
Volume 57, Issue 4, Pages (April 2000)
The course of the remnant kidney model in mice
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
Volume 58, Issue 3, Pages (September 2000)
Increased parathyroid expression of klotho in uremic rats
Volume 66, Issue 6, Pages (December 2004)
Volume 64, Issue 1, Pages (July 2003)
Volume 81, Issue 2, Pages (January 2012)
Recent developments in the management of secondary hyperparathyroidism
Volume 72, Issue 11, Pages (December 2007)
Cheryl P. Sanchez, Yu-Zhu He, Ellen Leiferman, Norman J. Wilsman 
Volume 60, Issue 5, Pages (November 2001)
Control of uremic bone disease: Role of vitamin D analogs
Volume 61, Issue 6, Pages (June 2002)
Volume 55, Issue 4, Pages (April 1999)
Volume 61, Issue 4, Pages (April 2002)
Volume 54, Issue 6, Pages (January 1998)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 67, Issue 2, Pages 467-476 (February 2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism  Matthew Colloton, Edward Shatzen, Gerald Miller, Catherine Stehman-Breen, Michihito Wada, David Lacey, David Martin  Kidney International  Volume 67, Issue 2, Pages 467-476 (February 2005) DOI: 10.1111/j.1523-1755.2005.67103.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Administration of cinacalcet HCl reduces parathyroid hyperplasia in 5/6 nephrectomy (Nx) rats. Male Sprague-Dawley rats were treated orally with cinacalcet HCl or vehicle daily for 4 weeks beginning 6 weeks post-5/6 nephrectomy. The values for proliferating cell nuclear antigen (PCNA)-positive cells are mean ± SEM of 9 to 17 sections. One section per parathyroid was taken for PCNA-positive cell analysis. ***P < 0.001 cinacalcet HCl–treated animals vs. vehicle-treated animals. Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Sections from rat parathyroid glands (400×) (A) 5/6 nephrectomy vehicle, (B) 5/6 nephrectomy cinacalcet HCl 10 mg/kg, (C) sham vehicle, and (D) sham cinacalcet HCl 10 mg/kg. Proliferating cell nuclear antigen (PCNA)-positive cells are shown as brown staining. Arrows indicate positive cells (400×) (A to D). Cinacalcet HCl (B) treatment for 4 weeks in 5/6 nephrectomized animals decreases parathyroid gland proliferation when compared to vehicle-treated 5/6 nephrectomized animals (A). Cinacalcet HCl has no effect on parathyroid gland proliferation in sham-operated animals (C and D). Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Ileum taken from a rat receiving either 5/6 nephrectomy treated with vehicle (A) or cinacalcet HCl 10 mg/kg (B). Proliferating cell nuclear antigen (PCNA)-positive cells are shown as brown staining. Arrows indicate positive cells (400×). There is no apparent difference in cell proliferation in drug versus vehicle-treated animals. Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Serum parathyroid hormone (PTH) (A) and blood ionized calcium (B) levels in 5/6 nephrectomized rats treated daily with oral cinacalcet HCl (•) 10 mg/kg(N = 10); (▪) 5 mg/kg(N = 10); (▴) 1 mg/kg(N = 5); or (○) vehicle mL/kg(N = 10)for 4 weeks starting 6 weeks post-5/6 nephrectomy. Serum samples were taken 2 hours after dosing. 5/6 nephrectomy animals treated with cinacalcet HCl had overall significant (P < 0.0001) lower serum PTH and blood ionized calcium levels. Post hoc analysis showed significant differences (*P < 0.05) between treated vs. controls at 8 and 10 weeks. Control normal animals received no treatments (□). Values represent mean ± SEM (N = 5 to 10 animals per dose group). Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Sham operated rats treated with daily oral cinacalcet HCl (•) 10 mg/kg(N = 5); (▪) 5 mg/kg(N = 5); (▴) 1 mg/kg(N = 3); or (○) vehicle mL/kg(N = 6)for 4 weeks starting 6 week post-sham surgery. There was an overall significant (P < 0.001) treatment effect of cinacalcet HCl on serum parathyroid hormone (PTH) (A) and blood ionized calcium levels (B) in serum samples taken 2 hours after dosing. Post hoc analysis revealed significant (*P < 0.05) decreases in serum PTH levels in the 10 mg/kg dose group at 8 and 10 weeks and at 10 weeks in the 5 mg/kg group. Blood ionized calcium was significant post hoc for all doses at the 8- and 10-week time points. Control normal animals received no treatment or surgery (□). Values represent mean ± SEM (N = 3 to 6 animals per dose group). Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Analysis of the correlations between serum levels of blood ionized calcium, phosphorus, or parathyroid hormone (PTH) with parathyroid weight in 5/6 nephrectomized animals receiving cinacalcet HCl (10 mg/kg) (closed symbols) or vehicle (open symbols). Kidney International 2005 67, 467-476DOI: (10.1111/j.1523-1755.2005.67103.x) Copyright © 2005 International Society of Nephrology Terms and Conditions